No Detail Found!

Frequency of factor VIII (FVIII) inhibitor in haemophilia A.

Author(s)
Munira Borhany Department of Haemostasis and Thrombosis, National Institute of Blood Disease & Bone Marrow Transplantation, Karachi, Pakistan
Meena Kumari Department of Haemostasis and Thrombosis, National Institute of Blood Disease & Bone Marrow Transplantation Karachi, Pakistan
Tahir Shamsi Department of Haemostasis and Thrombosis, National Institute of Blood Disease & Bone Marrow Transplantation, Karachi, Pakistan
Arshi Naz Department of Haemostasis and Thrombosis, National Institute of Blood Disease & Bone Marrow Transplantation, Karachi, Pakistan
Tasneem Farzana Department of Haemostasis and Thrombosis, National Institute of Blood Disease & Bone Marrow Transplantation, Karachi, Pakistan
Abstract
Objective: To determine the frequency of factor VIII specific inhibitors in haemophilia A. Study Design: Cross-sectional study. Place and Duration of Study: National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, from August 2007 to March 2009. Methodology: Venous blood samples of diagnosed haemophilia A patients were collected in tubes containing 0.109 M (3.2%) trisodium citrate, centrifuged without delay at 1200 G for 15 minutes. Factor VIII inhibitors were screened by APTT based method using 50:50 patients plasma mixed with normal plasma incubated together for 2 hours at 37°C. Quantitative assay was carried out to measure Bethesda units (BU). Samples were labelled as low titre inhibitor when less than 5 BU detected, while high titre inhibitor when more than 5 BU were detected. Results: A total of 140 Haemophilia A patients were evaluated for allo-antibodies who received treatment with FVIII concentrates / FFP/ cryoprecipitate. Among them 21 patients (15%) were found to have positive screening test results for inhibitors. The mean age of patients with inhibitors was 11.9 + 8.81 years. Thirteen were high responders (62%) while 8 were low responders (38%). The mean inhibitor level in low (titre) responders was 2.46 + 1.31 BU while in high (titre) responders it was 29.15 + 12.81 BU. According to severity of the disease 12/21 with severe haemophilia A (57.2%) developed inhibitors, whereas 8/21 with moderate (38%) and 1/21 with mild haemophilia A (4.7%) showed positive results for inhibitors. Conclusion: Fifteen percent haemophilia A patients developed inhibitors in this cohort, majority with severe and moderate haemophilia A. Age and severity of disease were found to be main contributing factors in patients who developed inhibitors.
Publication Details
Page(s) 289-293
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 22, Issue: 5, Year: 2012

Request the full text from PASTIC

0

Citations

0

Downloads

172

Views